These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Modification of oncolytic adenovirus and its application in cancer therapy. Liang Y; He J; Zhao Y Discov Med; 2020; 30(161):129-144. PubMed ID: 33593481 [TBL] [Abstract][Full Text] [Related]
24. Oncolytic Virotherapy for Malignant Tumor: Current Clinical Status. Zhang Y; Liu Z Curr Pharm Des; 2019; 25(40):4251-4263. PubMed ID: 31682207 [TBL] [Abstract][Full Text] [Related]
26. Novel Oncolytic Herpes Simplex Virus 1 VC2 Promotes Long-Lasting, Systemic Anti-melanoma Tumor Immune Responses and Increased Survival in an Immunocompetent B16F10-Derived Mouse Melanoma Model. Uche IK; Fowlkes N; Vu L; Watanabe T; Carossino M; Nabi R; Del Piero F; Rudd JS; Kousoulas KG; Rider PJF J Virol; 2021 Jan; 95(3):. PubMed ID: 33177208 [TBL] [Abstract][Full Text] [Related]
27. Oncolytic viruses in cancer therapy. Vähä-Koskela MJ; Heikkilä JE; Hinkkanen AE Cancer Lett; 2007 Sep; 254(2):178-216. PubMed ID: 17383089 [TBL] [Abstract][Full Text] [Related]
28. Oncolytic virus therapy for cancer: the first wave of translational clinical trials. Patel MR; Kratzke RA Transl Res; 2013 Apr; 161(4):355-64. PubMed ID: 23313629 [TBL] [Abstract][Full Text] [Related]
29. Targeted and armed oncolytic poxviruses for cancer: the lead example of JX-594. Breitbach CJ; Thorne SH; Bell JC; Kirn DH Curr Pharm Biotechnol; 2012 Jul; 13(9):1768-72. PubMed ID: 21740365 [TBL] [Abstract][Full Text] [Related]
31. Oncolytic virus therapy using genetically engineered herpes simplex viruses. Todo T Front Biosci; 2008 Jan; 13():2060-4. PubMed ID: 17981691 [TBL] [Abstract][Full Text] [Related]
32. [Oncolytic viruses as a new way of treatment of neoplastic diseases]. Kukla U; Chronowska J; Łabuzek K; Okopień B Pol Merkur Lekarski; 2015 Aug; 39(230):116-21. PubMed ID: 26319388 [TBL] [Abstract][Full Text] [Related]
33. Oncolytic Virotherapy by HSV. Watanabe D; Goshima F Adv Exp Med Biol; 2018; 1045():63-84. PubMed ID: 29896663 [TBL] [Abstract][Full Text] [Related]
35. Oncolytic viruses: what to expect from their use in cancer treatment. Terrível M; Gromicho C; Matos AM Microbiol Immunol; 2020 Jul; 64(7):477-492. PubMed ID: 31663631 [TBL] [Abstract][Full Text] [Related]
36. Oncolytic Viruses in Cancer Treatment: A Review. Lawler SE; Speranza MC; Cho CF; Chiocca EA JAMA Oncol; 2017 Jun; 3(6):841-849. PubMed ID: 27441411 [TBL] [Abstract][Full Text] [Related]
38. Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going? Turnbull S; West EJ; Scott KJ; Appleton E; Melcher A; Ralph C Viruses; 2015 Dec; 7(12):6291-312. PubMed ID: 26633468 [TBL] [Abstract][Full Text] [Related]
39. Engineering and combining oncolytic measles virus for cancer therapy. Leber MF; Neault S; Jirovec E; Barkley R; Said A; Bell JC; Ungerechts G Cytokine Growth Factor Rev; 2020 Dec; 56():39-48. PubMed ID: 32718830 [TBL] [Abstract][Full Text] [Related]
40. The emerging role of viruses in the treatment of solid tumours. Bourke MG; Salwa S; Harrington KJ; Kucharczyk MJ; Forde PF; de Kruijf M; Soden D; Tangney M; Collins JK; O'Sullivan GC Cancer Treat Rev; 2011 Dec; 37(8):618-32. PubMed ID: 21232872 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]